Accolade Pharmaceuticals Launches Specialty Company to Repurpose Approved Drugs for Allergic Disease

WILMINGTON, Del.—Six former drug industry executives have announced today the formation of Accolade Pharmaceuticals LLC, a specialty biopharmaceutical company focused on developing a range of products for the treatment of allergic disorders. The Company will focus its initial development activities on repurposing a FDA approved drug for asthma for broader clinical use in treating allergic related conditions.

Accolade’s lead drug candidate is zafirlukast, a Leukotriene Receptor Antagonist (LTRA), also known as a leukotriene inhibitor, which blocks the action of leukotriene receptors- part of the body’s inflammatory response system in order to reduce inflammation, the constriction of airways, and the buildup of mucus in the lungs. Zafirlukast, marketed as Accolate® by AstraZeneca, is currently available solely in oral form and is only used as a preventative measure for the treatment of asthma attacks. Accolade is actively pursuing development on several topical formulations of the drug, including a topical inhaled formulation for the treatment of asthma as well as other topical formulations for the treatment of allergic rhinitis and inflammatory eye and skin disorders.

“Allergic diseases are a big medical issue and about 30% of people worldwide suffer from some form of allergic symptoms. While advances in diagnosis and treatment have been substantial, there remain significant unmet needs that can be addressed with well-known and safe drugs such as zafirlukast through improvement of drug delivery. We are delighted to launch our Company with the mission of providing new treatment options for patients,” says John Mohr, Co-Founder and Chief Executive Officer for Accolade Pharmaceuticals LLC.

Inhaled zafirlukast will be the first product to enter Accolade’s pipeline and is currently in its pre-clinical stage. It is anticipated to enter Phase I/II FDA clinical trials within the year.

For more information on Accolade Pharmaceuticals LLC, please visit: